Current Report Filing (8-k)
May 20 2016 - 4:43PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 19, 2016
|
|
|
|
CVS HEALTH CORPORATION
|
(Exact Name of Registrant
as Specified in Charter)
|
|
|
Delaware
|
|
|
(State or Other Jurisdiction of Incorporation)
|
|
|
001-01011
|
|
05-0494040
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
|
One CVS Drive
Woonsocket, Rhode Island
|
|
02895
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
|
|
|
Registrant’s telephone number, including area code:
(401) 765-1500
|
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
|
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.07. Submission of Matters to a Vote of Security Holders.
The following are the voting results on each matter submitted to the stockholders of CVS Health Corporation (the “Company”) at the Annual Meeting of Stockholders held on May 19, 2016 (the “Annual Meeting”). The proposals below are described in detail in the proxy statement filed by the Company on April 8, 2016 (the “Proxy Statement”). At the Annual Meeting, the 11 nominees for director were elected to the Company’s Board of Directors for a term of one year (Proposal 1). In addition, management proposals regarding the ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for 2016 (Proposal 2) and a non-binding resolution regarding approval of the compensation of the Company’s named executive officers as disclosed in the Proxy Statement (Proposal 3), were approved. Stockholder proposals requesting a report on the alignment of the Company’s political contributions and its corporate values (Proposal 4) and requesting a report on executive pay (Proposal 5) were rejected.
|
|
|
|
|
|
|
|
For
|
Against
|
Abstained
|
Broker Non-Votes
|
1.
The election, for one-year terms, of
persons nominated for directors, all
as set forth in the Company’s Proxy
Statement, was approved by the
following votes:
|
|
|
|
|
|
|
|
|
|
Richard M. Bracken
|
859,502,292
|
3,804,506
|
1,440,150
|
94,836,171
|
|
C. David Brown II
|
841,683,831
|
21,560,921
|
1,502,196
|
94,836,171
|
|
Alecia A. DeCoudreaux
|
860,979,464
|
2,379,419
|
1,388,065
|
94,836,171
|
|
Nancy-Ann M. DeParle
|
861,189,576
|
2,137,657
|
1,419,715
|
94,836,171
|
|
David W. Dorman
|
842,438,086
|
20,808,559
|
1,500,303
|
94,836,171
|
|
Anne M. Finucane
|
849,557,041
|
13,779,452
|
1,410,455
|
94,836,171
|
|
Larry J. Merlo
|
860,638,963
|
2,867,708
|
1,240,277
|
94,836,171
|
|
Jean-Pierre Millon
|
859,945,355
|
3,321,076
|
1,480,517
|
94,836,171
|
|
Richard J. Swift
|
779,563,716
|
81,927,589
|
3,255,643
|
94,836,171
|
|
William C. Weldon
|
843,115,815
|
20,078,999
|
1,552,134
|
94,836,171
|
|
Tony L. White
|
843,915,782
|
19,320,097
|
1,511,069
|
94,836,171
|
|
|
|
|
|
|
2.
Ratification of the appointment of
Ernst & Young LLP as the
Company’s independent registered
public accounting firm for the 2016
fiscal year, as set forth in the
Company’s Proxy Statement, was
approved by the following vote:
|
950,956,355
|
6,745,154
|
1,881,610
|
—
|
|
3.
Company proposal to approve, by a
non-binding vote, the compensation
of the Company’s named executive
officers, as set forth in the
Company’s Proxy Statement, was
approved by the following vote:
|
689,956,751
|
169,784,623
|
5,005,574
|
94,836,171
|
|
4.
Stockholder proposal requesting a
report on the congruency of the
Company’s political contributions and its corporate values was rejected by
the following vote:
|
48,687,102
|
695,391,620
|
120,668,226
|
94,836,171
|
|
5.
Stockholder proposal requesting a
report on the Company’s
executive pay was rejected by
the following vote:
|
59,207,680
|
756,944,695
|
48,594,573
|
94,836,171
|
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
CVS HEALTH CORPORATION
|
|
|
|
|
|
|
|
By:
|
/s/ Colleen M. McIntosh
|
|
|
|
Colleen M. McIntosh
Senior Vice President and
Corporate Secretary
|
|
|
|
Dated: May 20, 2016
|
|
|
|
|
CVS Health (NYSE:CVS)
Historical Stock Chart
From Apr 2024 to May 2024
CVS Health (NYSE:CVS)
Historical Stock Chart
From May 2023 to May 2024